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Autocrine IGF2 programmes 
β‑cell plasticity under conditions 
of increased metabolic demand
Ionel Sandovici1,2,3,9*, Constanze M. Hammerle1,2,7,9*, Sam Virtue1, Yurena Vivas‑Garcia4,8, 
Adriana Izquierdo‑Lahuerta4, Susan E. Ozanne1, Antonio Vidal‑Puig1,5,6, 
Gema Medina‑Gómez4 & Miguel Constância1,2,3* 
When exposed to nutrient excess and insulin resistance, pancreatic β‑cells undergo adaptive changes 
in order to maintain glucose homeostasis. The role that growth control genes, highly expressed in 
early pancreas development, might exert in programming β‑cell plasticity in later life is a poorly 
studied area. The imprinted Igf2 (insulin‑like growth factor 2) gene is highly transcribed during 
early life and has been identified in recent genome‑wide association studies as a type 2 diabetes 
susceptibility gene in humans. Hence, here we investigate the long‑term phenotypic metabolic 
consequences of conditional Igf2 deletion in pancreatic β‑cells (Igf2βKO) in mice. We show that 
autocrine actions of IGF2 are not critical for β‑cell development, or for the early post‑natal wave of 
β‑cell remodelling. Additionally, adult Igf2βKO mice maintain glucose homeostasis when fed a chow 
diet. However, pregnant Igf2βKO females become hyperglycemic and hyperinsulinemic, and their 
conceptuses exhibit hyperinsulinemia and placentomegalia. Insulin resistance induced by congenital 
leptin deficiency also renders Igf2βKO females more hyperglycaemic compared to leptin‑deficient 
controls. Upon high‑fat diet feeding, Igf2βKO females are less susceptible to develop insulin resistance. 
Based on these findings, we conclude that in female mice, autocrine actions of β‑cell IGF2 during early 
development determine their adaptive capacity in adult life.
Glucose homeostasis relies on pancreatic β-cells’ ability to adapt their insulin output to meet the sensitivity of 
tissues such as the liver, skeletal muscle and fat to insulin. Insulin production can be augmented in two main ways: 
firstly, by increasing the amount produced by each β-cell, or secondly through β-cell hyperplasia (i.e. expand-
ing β-cell mass via cell proliferation). Failure of these compensatory responses in the face of insulin resistance, 
such as during obesity, pregnancy or ageing can lead to the development of  diabetes1. So far, several extrinsic 
stimuli that control the adaptive expansion of β-cell mass, as well as processes intrinsic to β-cells, which medi-
ate their response to an increased demand for insulin, have been  identified2,3. The intrauterine milieu, which is 
determined by both genetic and non-genetic factors, appears to be critical for normal β-cell development and 
future adaptability to metabolic stress across the  lifecourse4. Recent genome-wide association studies (GWAS) 
have identified several loci linked with decreased fetal growth and increased risk for type 2 diabetes (T2D), as 
well as alleles associated with higher birth weight and higher T2D  risk5. Among these, three loci are located in 
regions regulated by genomic imprinting, including INS-IGF2, RB1 and DLK16.
Insulin-like growth factor 2 (IGF2) is a major growth factor during fetal  life7. Igf2 is transcribed from the 
paternally inherited allele in most  tissues8, and its expression in all tissues is dramatically down-regulated in 
mice around  weaning9. In human, IGF2 expression also declines with age, although significant activity is retained 
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during adult  life9,10. Previous studies suggested that IGF2 is required for β-cell development and function. How-
ever, much of this evidence stems from in vitro studies or analyses performed with gain-of-function rodent 
models, and can be summarised as follows: (1) rat β-cells overexpressing Igf2 from a transgene were protected 
from interleukin-1β (IL-1β) cytokine-induced apoptosis ex vivo11 and islets isolated from neonatal rats were 
protected from cytokine-induced apoptosis when cultured in the presence of  IGF212; (2) diabetic rats transplanted 
with islets overexpressing Igf2 had improved glucose tolerance compared to diabetic rats transplanted with 
standard islets, and β-cell replication rate was higher in Igf2-overexpressing islets compared to control islets after 
 transplantation13; (3) Goto-Kakizaki (GK) rats that develop spontaneous diabetes had decreased IGF2 protein 
levels in their pancreatic bud, prior to the onset of the β-cell mass  reduction14; (4) transgenic mice with global 
Igf2 overexpression had larger pancreatic islets at the end of gestation, with increased cell replication and reduced 
 apoptosis15; (5) transgenic mice with overexpression of Igf2 in β-cells under the control of rat insulin I promoter 
had a threefold expansion of β-cell mass, with disrupted islet morphology, hyperglycaemia when fed a standard 
chow diet and overt diabetes when fed high fat diet (HFD)16; and (6) conditional Igf2 deletion in pancreatic 
β-cells led to reduced glucose-stimulated insulin secretion (GSIS) in 24–26 weeks-old females fed chow diet, 
and lower GSIS in both sexes after 18 weeks of HFD feeding, associated with reduced β-cell mass in  females17.
We recently characterised Igf2 expression in the main pancreatic cell lineages during perinatal  life18. We 
observed that at embryonic day 16 (E16) there was significant Igf2 expression in pancreatic β-cells, which 
then declines rapidly after birth, being approximately two orders of magnitude lower from weaning onwards. 
However, we also found that the main pancreatic cell lineage expressing Igf2 throughout perinatal life was that 
of mesenchyme-derived  cells18. Accordingly, conditional Igf2 deletion in the pancreatic mesenchyme, driven 
by Nkx3.2-Cre, led to a smaller pancreas, with reduced acinar and β-cell mass and altered glucose homeostasis 
when mutant females became  pregnant18. This study highlighted an important role for pancreatic mesenchyme 
IGF2 in paracrine growth signalling, including the β-cell. One area that remains poorly understood is if, and 
how, fetal growth control genes expressed in the β-cell, such as Igf2, are involved in programming of diabetes 
susceptibility in later life. Data from Modi et al.17, and our own data on conditional Igf2 deletions in the pancreatic 
endocrine lineage (Ptf1a-Cre)18, suggest that in normal physiological conditions, deletion of Igf2 from β-cells 
or its precursors, have little effect on β-cell biology. However, several questions remain to be elucidated: (1) Is 
β-cell remodelling, which occurs in the early postnatal  period19, affected by the embryonic deletion of β-cell Igf2? 
(2) Is β-cell mass  expansion20 and/or glucose homeostasis impaired in pregnant mothers that lack Igf2 in their 
β-cells? If yes, does it have consequences for the growth and metabolism of their offspring? (3) Does congenital 
 obesity21 or HFD-induced  obesity22, together with embryonic deletion of β-cell Igf2 result in early programming 
of diabetes? By addressing these questions, we therefore aim at testing the possibility that autocrine actions of 
IGF2 in pancreatic β-cells during early life may program their ability to adapt to physiological challenges or 
conditions that cause insulin resistance throughout the life-course.
Results
Autocrine IGF2 is not required for early postnatal β‑cell remodelling and function. We achieved 
conditional deletion of the paternal Igf2 allele in pancreatic β-cells (Igf2βKO) (Fig. 1a) by crossing heterozygous 
Igf2 floxed male mice (Igf2+/fl)18 with homozygous RIP-Cre female mice that carry a Cre transgene under the 
control of the rat Ins2 (insulin 2)  promoter23. We used a recombinase-inducible YFP reporter under the control 
of the Rosa26 locus (Rosa26YFP-stopfl/fl)24, which enabled us to isolate pancreatic β-cells using Fluorescence 
Activated Cell Sorting (FACS) to verify for efficiency and specificity of Igf2 deletion. (Supplemental Fig. S1a–e). 
Paternal Igf2βKO resulted in ~ 96% reduction of its mRNA levels in pancreatic β-cells isolated by FACS at post-
natal day 2 (P2) (Fig. 1b). In contrast, Igf2 mRNA levels were similar between Igf2βKO and littermate controls in 
several other tissues tested, including in the hypothalamus (Fig. 1b), in which we observed only very few isolated 
YFP + cells (Supplemental Fig. 1f), in agreement with previous  studies25.
Figure 1.  Impact of Igf2βKO on β-cell remodelling and glucose homeostasis in early postnatal life. (a) Schematic 
representation of the Igf2 wild-type allele (top) floxed allele (middle) and Cre-mediated deletion of the region 
flanked by LoxP sites (bottom) and PCR genotyping strategy showing complete deletion (Del) in pancreatic 
β-cells isolated by FACS, but no evidence for deletion in non β-cells (NTC—no template control, L—100 bp 
DNA ladder). See also the uncropped gel picture in Supplemental Fig. S1e. (b) Assessment of Igf2 deletion 
efficiency and specificity by qRT-PCR at postnatal day 2 (P2). Data was normalised to Ppia, Gapdh and Sdha, 
used as internal controls (n = 4—12 samples/group). Residual Igf2 mRNA levels in β-cells isolated from Igf2βKO 
compared to controls is shown as %. (c) RNA-seq analysis of Igf2 expression levels (TPM—transcripts per 
million) in pancreatic β-cells isolated by FACS (n ≥ 2 at each developmental stage), showing a rapid decline at 
mRNA level in post-natal life (data derived from Qiu et al.26). (d) Left: representative examples of P10 pancreatic 
sections stained for EdU (red—marker of cell proliferation), insulin (INS, green—staining β-cells) and Hoescht 
(blue—staining nuclei). Right: quantification of proliferating β-cells  (EdU+/INS+) (n = 5–10 samples/group). (e) 
Left: representative examples of P10 pancreatic sections stained for TUNEL (red—marker of cell apoptosis), 
insulin (INS, green—staining β-cells) and Hoescht (blue—staining nuclei). Right: quantification of apoptotic 
β-cells  (TUNEL+/INS+) (n = 3–9 samples/group). (f) Measurement of pancreatic β-cell mass using stereology at 
P5 and P14 (n = 5–7 samples/group). (g) Measurement of total pancreatic insulin content at P14, adjusted for 
total protein content (n = 9 samples/genotype). (h) Non-fasting glucose levels in peripheral blood at P5, P10 and 
P14 (n = 6–14 samples/group). Scale bars in (d) and (e) are 50 µm. For all graphs, data is shown as individual 
values, with averages ± S.D. (standard deviation). P values shown above the graphs correspond to t tests with 
Holm-Sidak correction for multiple testing in (b), two-way ANOVA tests in (d), (e), (f) and (h) and a Mann–
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Analysis of recently published transcriptomes of bulk β-cells isolated by FACS at several developmental time 
points, spanning from E17.5 to  P6026, showed that Igf2 mRNA levels are relatively much higher in perinatal 
life and decline rapidly few days after birth (Fig. 1c), in line with our own previous  results18. To assess whether 
Igf2βKO alters the dynamics of the early postnatal wave of β-cell remodelling, we first studied rates of cell prolif-
eration at P5, P10 and P14 after intra-peritoneal administration of EdU (5-ethynyl-2′-deoxyuridine)27 for 6 h. 
The percentage of proliferating β-cells  (EdU+/INS+) was significantly affected by age, decreasing from ~ 6.6% at 
P5 to ~ 2.6% at P14 in controls (Fig. 1d). We observed a small genotype-dependent reduction of β-cell prolifera-
tion rate across the three ages studied (Fig. 1d). Rates of β-cell apoptosis  (TUNEL+/INS+) peaked around P10 
(Fig. 1e), as previously  reported19. However, there was no genotype-dependent difference in the frequency of 
apoptotic β-cells (Fig. 1e). Additional parameters measured in early postnatal life, including β-cell mass (Fig. 1f), 
total pancreatic insulin content (Fig. 1g) and non-fasting blood glucose levels (Fig. 1h) were similar between 
Igf2βKO mutants and littermate controls. Altogether, our results show that the autocrine actions of IGF2 are not 
required for β-cell remodelling or function in early postnatal life.
Igf2βKO does not alter glucose homeostasis in adult mice fed standard chow diet. In order to 
estimate the impact of Igf2βKO on body growth and glucose homeostasis in adult life, we followed up a cohort of 
Figure 2.  Impact of Igf2βKO on body growth and glucose homeostasis in adult mice fed a standard chow diet. 
(a) Growth kinetics (n = 4–13 females/genotype and n = 8–13 males/genotype). Glucose tolerance tests with 
glucose administered by intra-peritoneal injections (ipGTTs) after over-night fasting performed in females 
(b) and males (c). First three panels show changes in blood glucose concentrations (y-axis), from basal pre-
treatment values, with time (x-axis), after glucose administration. The graphs on the far right in (b) and (c) show 
area under curve (AUC) calculated during ipGTTs using the trapezoid rule and normalised to basal glucose 
levels (n = 4–13 females/genotype and n = 8–13 males/genotype). Data is presented as averages ± SD [panel (a)] 
or SEM [first three panels in (b) and (c)] or individual values with averages ± SD [fourth panel in (b) and (c)]. P 
values shown above graphs were calculated by mixed-effects model tests [panel (a)] or two-way ANOVA tests 
[panels (b) and (c)]. NS non-significant.
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mutant mice and littermate controls fed with a regular chow diet from weaning up to the age of 48 weeks. Both 
sexes displayed similar age-related weight gain, without any significant genotype-related difference (Fig. 2a). 
We monitored the impact on glucose homeostasis in both sexes by performing intra-peritoneal glucose toler-
ance tests (ipGTTs) after an overnight fast at the ages of 4, 17 and 39 weeks (Fig. 2b,c). Within the age range 
of our study, we observed significant age-related glucose intolerance only in males, as assessed by area under 
curve (AUC) analyses (Fig. 2c). However, neither sex had significant differences in AUC related to genotype 
(Fig. 2b,c). We also performed standard serum biochemistry profiling at the end of the study (i.e., at the age of 
48 weeks) after overnight fasting. The lipid profile showed sex-related differences, with levels of triglycerides, 
free fatty acids and cholesterol being significantly higher in males than in females but levels of these lipids were 
similar between the two genotypes in both sexes (Supplemental Fig. 2a). Corticosterone levels were lower in 
males than in females, but similar between mutants and controls (Supplemental Fig. 2b). Additionally, there 
was no significant sex-related or genotype-related differences in glucose and insulin levels after an overnight fast 
(Supplemental Fig. 2c). Therefore, we conclude that ablation of Igf2 in pancreatic β-cells does not alter glucose 
or insulin homeostasis during adult life in mice fed a regular chow diet.
Pregnant Igf2βKO females have altered glucose homeostasis, with an impact on fetal develop-
ment. After establishing that the autocrine actions of pancreatic β-cell IGF2 are not required for the normal 
function of these cells, from in utero development up until 39 weeks of age under physiological conditions, the 
next goal was to find out if pancreatic β-cell IGF2 was necessary for β-cell plasticity during pregnancy, when 
demands for insulin  increase20. To study the impact of Igf2βKO on maternal adaptation to pregnancy, 6-to-8 week 
old Igf2βKO and control females were timed-mated with wild-type males and analyses were performed on embry-
onic days E15 (i.e. at the peak of pregnancy-associated insulin  resistance20) and E19 (near term). Total body 
weight gain during pregnancy, litter sizes and pancreas weights were indistinguishable between the two gen-
otypes (Supplemental Fig. 3a–c). Non-fasting glucose levels decreased as gestation progressed, but remained 
comparable between the two genotypes (Fig.  3a). However, while in control females non-fasting circulating 
insulin levels increased at E15 and then returned to levels similar to non-pregnant females by E19, insulin levels 
remained elevated in mutant females during late gestation, being significantly higher at E19 compared to control 
females (Fig. 3a). Hyperinsulinemia in pregnant Igf2βKO females was not associated with increased pancreatic 
β-cell mass, which was similar to controls at E19 (Fig. 3b). We did not find evidence of impaired insulin sensitivity 
in periphery driving the observed hyperinsulinemia at E19, with levels of well-established metabolic biochemi-
cal markers such as leptin, adiponectin and  resistin28 being similar between the two genotypes (Supplemental 
Fig. 3d). The expected pregnancy-associated patterns (i.e. increased levels of leptin and resistin and decreased 
levels of adiponectin compared to non-pregnant control females) were observed (Supplemental Fig. 3d). At E15, 
after six hours of fasting, the pregnant Igf2βKO mouse exhibited hyperglycaemia compared to pregnant controls, 
while fasting insulin levels remained comparable between the two genotypes (Fig. 3c). However, oral glucose 
tolerance tests (OGTTs) did not show significant differences between the two genotypes at E15 (Fig. 3d).
Next, we assessed whether maternal hyperglycaemia and hyperinsulinemia observed in Igf2βKO females in 
late pregnancy had any impact on the growth and glucose metabolism of their conceptuses. Fetal weights were 
similar at both E15 and E19 (Fig. 3e). However, at E19, placental weights in Igf2βKO pregnancies showed a small 
but statistically significant increase (5%) compared to those in control pregnancies (Fig. 3e). Levels of glucose in 
the fetal blood were indistinguishable in litters of Igf2βKO versus control mothers at both E15 and E19 (Fig. 3f). 
However, levels of insulin measured at E19 in individual fetuses were almost double in litters of Igf2βKO moth-
ers (Fig. 3e). Overall, our results show that Igf2βKO females have altered glucose homeostasis during pregnancy, 
associated with increased maternal and fetal insulinemia and larger placentae near term.
Igf2βKO females are less susceptible to develop HFD‑induced insulin resistance in adult-
hood. We next investigated whether HFD feeding can elicit altered glucose homeostasis in Igf2βKO mice. 
To this aim, we fed a cohort of Igf2βKO and control littermate mice with a standard chow diet from weaning 
(3 weeks) until the age of 28 weeks, after which half of the mice were fed HFD (60% kcal from fat) for the follow-
ing 13 weeks, while the remaining half were kept on the control chow diet. Measurements of body composition 
by TD-NMR at the ages of 8 and 28 weeks revealed significant age-related accrual in both fat and lean mass, 
without any significant genotype-related effects in either of the two sexes (Supplemental Fig. 4a,b). Between the 
ages of 28 and 40 weeks, both sexes gained significantly more weight when fed HFD (Fig. 4a). TD-NMR meas-
urements at the age of 40 weeks showed a significant increase in fat mass in the mice fed HFD for both sexes 
(Fig. 4b). Lean mass was significantly increased by HFD only in females (Fig. 4c). Neither fat mass, nor lean mass 
showed any significant differences related to the genotype (Fig. 4b,c). At the age of 40 weeks (i.e. 12 weeks after 
the HFD was introduced to half of the animals), all mice were subjected to insulin tolerance tests (ITTs), fol-
lowed a week apart by OGTTs. ITTs performed in females did not show any significant diet-related differences. 
However, there was a significant impact of the genotype, Igf2βKO females being less susceptible to develop insulin 
resistance than their littermate controls, as indicated by AUC analyses after correction to basal levels (Fig. 4d). 
On the contrary, ITTs performed in males revealed increased diet-associated insulin resistance, without any sig-
nificant impact of the genotype (Fig. 4e). OGTTs showed that both sexes displayed a small but significant glucose 
intolerance induced by HFD, without any impact of the genotype (Fig. 4f,g). To investigate further the improved 
insulin sensitivity observed in Igf2βKO females, we measured GSIS. Insulin levels were higher in females fed HFD 
at baseline and increased significantly more during OGTT (AUC P diet = 0.0142), without any significant impact 
of the genotype (Fig. 4h). β-cell mass, measured at the end of the experiment, was significantly higher in mice 
fed HFD for both sexes, without any difference related to the genotype (Fig. 4i). Overall, these data indicate that, 
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when fed HFD in adulthood, Igf2βKO mice retain the ability to adapt by expanding β-cell mass, and that Igf2βKO 
females are more insulin sensitive than their littermate controls.
Igf2βKO leads to exacerbated hyperglycaemia in females with congenital leptin deficiency. We 
next assessed the impact of Igf2βKO mutation in a model of genetic obesity and marked insulin resistance due to 
congenital leptin deficiency (Lepob/ob). Lepob/ob mice display severe obesity first recognisable at about four weeks 
of  age29. We generated litters with four genotypes (controls, Igf2βKO, Lepob/ob and Lepob/ob; Igf2βKO—Supplemental 
Fig. 5) and performed phenotypic analyses in young adult life (at the age of 8 weeks). For both sexes, mice in the 
ob/ob background were significantly obese, as expected, but there was no impact of Igf2βKO mutation on overall 
Figure 3.  Impact of Igf2βKO on glucose homeostasis in pregnant females and their developing conceptuses. (a) 
Non-fasting glucose and insulin levels measured in peripheral blood of 8–10 week old pregnant (E15 and E19) 
and non-pregnant (NP) females (n = 7–18/group). (b) Measurement of pancreatic β-cell mass by stereology 
in E19 pregnant females (n = 9 controls and n = 7 mutants). (c) Glucose and insulin levels measured after six 
hours of fasting in pregnant females (E15) (n = 15 controls and n = 14 mutants). (d) Left: oral glucose tolerance 
test (OGTT) performed in 8–10 week old pregnant females (E15) after 6 h of fasting. Changes in blood glucose 
concentrations (y-axis), from basal pre-treatment values, with time (x-axis), after glucose administration are 
shown. Right: AUC calculated using the trapezoid rule, normalised to basal glucose levels (n = 15 controls and 
n = 14 mutants). (e) Fetal and placental weights at E15 and E19 (n = 108–156 conceptuses/group). (f) Glucose 
and insulin levels in fetal blood (E19) measured after decapitation (n = 64 fetuses of control mothers and 
n = 54 fetuses of mutant mothers). Data is presented as individual values with averages ± SD [panels (a)–(c) 
and (d)—right side graph], averages ± SEM [panel (d)—left side graph], or box plots (25–75 percentiles), with 
whiskers extending down to the  5th percentile and up to the  95th percentile, and points below and above the 
whiskers drawn as individual points [panels (e) and (f)]. P values shown above the graphs were calculated by 
two-way ANOVA tests [panels (a), (e) and (f)—left side graph], unpaired t test with Welch’s correction [panel 
(b)], Mann–Whitney tests [panels (c), (d)—right side graph, and (f)]. ** correspond to p < 0.01 calculated by 
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body weight (Fig. 5a). Fasting glucose levels were also elevated in mice on the ob/ob background in both sexes 
(Fig. 5b). However, in females, but not in males, there was an additional significant increase in fasting glucose 
levels in Lepob/ob; Igf2βKO compared to Lepob/ob mice (Fig. 5b). For both sexes, ipGTTs showed significant glucose 
intolerance in mice on the ob/ob background (Fig. 5c). However, in both males and females, AUCs corrected 
to baseline were not statistically different between Lepob/ob and Lepob/ob; Igf2βKO mice (Fig. 5c). In females, we 
observed significant insulin resistance in mice on the ob/ob background, but with no further impact caused by 
the Igf2βKO mutation (Fig. 5d). In males, all four genotypes had similar levels of insulin sensitivity, as assessed 
by AUC analyses after normalising to the baseline glucose levels (Fig. 5d). Together, these results demonstrate 
that lack of Igf2 expression in pancreatic β-cells is detrimental in obese females with congenital leptin deficiency, 
leading to exacerbated hyperglycaemia in young adult life.
Discussion
This study strongly suggests that autocrine IGF2 actions in pancreatic β-cells during early life program their 
capacity to adapt under circumstances that require increased insulin production in adult life, in females. We 
first show that under normal physiological conditions Igf2βKO is compatible with normal pancreatic β-cell devel-
opment, remodelling and function during early postnatal life, in both males and females. In the absence of a 
metabolic challenge, Igf2βKO is also compatible with normal glucose homeostasis during adult life.
We then exposed Igf2βKO and littermate control mice to several models of increased metabolic demand leading 
to insulin resistance and therefore need for increased insulin release. Firstly, we challenged Igf2βKO via pregnancy, 
a physiological condition associated with reduced insulin sensitivity in the latter  stages20. After six hours fasting, 
Igf2βKO females became hyperglycaemic at E15, with normal levels of insulin and normal clearance of glucose 
from periphery during OGTT. These observations suggest that at this stage of pregnancy, Igf2βKO females cannot 
reach the level of β-cell compensation required to maintain glucose homeostasis. We did not perform fasting 
glucose/insulin measurements or OGTTs at the end of gestation (E19). Therefore, we can’t rule out that, in the 
fasting state, Igf2βKO females are hyperglycaemic at both time points or that they are glucose intolerant only at 
E19. However, we found that non-fasted Igf2βKO females were normoglycaemic at both time points and exhibited 
hyperinsulinemia, in particular at E19, suggesting continued β-cell maladaptation. The effects observed in off-
spring provide evidence supporting the proposed maternal β-cell maladaptation. Accordingly, and although the 
conceptuses had normal development and growth up until at least E15, at E19 they associated placentomegaly 
and hyperinsulinemia. We did not identify the signal that triggers the observed changes in the conceptus. Given 
the known roles of placenta in mediating nutrient transfer between the mother and the  fetus30, as well as the 
role played by several placental hormones in mediating maternal adaptations during  pregnancy31, we propose 
that the observed changes in the mother and the fetus are interconnected. We speculate that the fetus is sens-
ing intermittent episodes of maternal hyperglycaemia and adapting through increased production of insulin. 
In turn, fetal hyperinsulinemia elicit placentomegalia, with excessive secretion of placental hormones, perhaps 
leading to maternal hyperinsulinemia at the end of gestation. It would be interesting to assess in future studies 
whether the hyperinsulinemia observed in the fetuses of Igf2βKO females at E19 is due to changes in fetal β-cell 
mass, or is caused by increased glucose-mediated insulin secretion, and has a long-lasting impact on their post-
natal growth and metabolism. Similarly to our model, fetal hyperinsulinemia has been reported in liver-specific 
insulin receptor knockout mice (LIRKO), which results from sustained maternal hyperinsulinemia and transient 
increase in blood glucose concentrations during  pregnancy32. Additionally, foetuses from mildly diabetic rat 
mothers (diabetes induced by streptozotocin administration prior to mating) show normal body weight, pla-
centomegalia, higher pancreatic and plasma insulin concentrations at the end of gestation and enhanced insulin 
secretion by fetal pancreatic β-cells in response to glucose stimulation in vitro33. It would also be compelling to 
explore whether the metabolic changes observed during the first pregnancy in Igf2βKO female mice become more 
pronounced in subsequent pregnancies, e.g. leading to diabetes. Women with gestational diabetes (GDM) have 
increased risk of recurrent GDM because of their underlying β-cell  impairment34. Furthermore, previous GDM 
is an important predicting factor for subsequent diagnosis of diabetes in later  life35.
The next model of increased metabolic demand used in this study was the exposure to a diet with high 
content in fat (HFD), known to induce obesity and insulin  resistance22. We observed that Igf2βKO females, but 
not the males, are more resistant to developing HFD-induced insulin resistance. However, the impact of Igf2βKO 
mutation on insulin sensitivity in females fed HFD is relatively mild, with no impact on other variables meas-
ured. Additional tests such as hyperinsulinemic-euglycaemic glucose clamps, which allow a direct assessment 
of insulin resistance and glucose uptake by peripheral  tissues36, would further refine the impact of Igf2βKO on 
β-cell physiology in mice exposed to HFD. Our finding suggests the possibility of secreted signal(s) originating 
from pancreatic β-cells and affecting insulin sensitivity in the periphery. Our current knowledge of the β-cell 
secretome is  limited37,38 but a very recent study uncovered the role of β-cell–derived exosomes that regulate 
peripheral insulin sensitivity in a paracrine manner via microRNA-26a (miR-26a)39. Future studies could explore 
the impact of autocrine IGF2 in regulating β-cell secretome.
An additional model of increased metabolic demand used in this study was that of congenital leptin 
 deficiency22. In Lepob/ob mutants, Igf2βKO led to augmented hyperglycaemia but only in females. It is interesting 
to observe that in two models of increased metabolic demand (congenital leptin deficiency and pregnancy), 
Igf2βKO females exhibited hyperglycaemia, while in the third (HFD feeding) Igf2βKO females were normoglycae-
mic and more insulin sensitive than their controls. We speculate that these outcome differences may relate to 
the diets used (chow diets are high in carbohydrates and low in lipids, while the HFD used in this study is high 
in lipids and low in carbohydrates) that trigger divergent insulin actions, as recently  reviewed40. Based on the 
observations made in this study, we suggest that autocrine IGF2 may be more critical under circumstances with 
increased metabolic demand in females.
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A number of previous studies proposed several molecular mechanisms by which autocrine IGF2 controls 
β-cell physiology. These range from protection against β-cell apoptosis (via a GLP-1-mediated increase in IGF1R 
expression)41, to promoting β-cell proliferation during pregnancy (dependent on estrogen, which reduces the 
expression of miR-338-3p, leading to increased IGF1R expression)17 and to controlling fasting insulin secretion 
(via IGF1R-AKT2-FAK signalling)42. However, these molecular mechanisms were based on observations made 
in vitro in insulin-secreting cell lines or in primary β-cells or pancreatic islets cultured ex vivo and require in vivo 
testing to be substantiated.
In a previous study, Modi et al. reported a more substantial impact of autocrine IGF2 on β-cell function 
using the same approach of a conditional deletion of Igf2 in pancreatic β-cells17. Contrary to our observations, 
Modi et al. observed impaired β-cell expansion during pregnancy in Igf2βKO females. Likewise, when fed HFD, 
they recorded significantly worsened glucose tolerance in Igf2βKO females compared to controls. However, there 
are some significant differences between the experimental setup of the two studies, which may account for the 
phenotypic differences observed. First, we performed our experiments under a homogeneous C57BL/6 J genetic 
background. In contrast, Modi et al.17 used a mixed 129S6/C57BL/6 background. It is known that C57BL/6 and 
129S6 strains exhibit notable differences in patterns of glucose homeostasis and insulin secretion under regular 
diet or when challenged with  HFD43. Second, Modi et al.17 used Ins1-Cre to achieve deletion of Igf2 in pancre-
atic β-cells, while we used RIP-Cre. RIP-Cre may have some weak ectopic activity in the  brain25. However, as 
shown in the results section, we did not see any significant change of Igf2 mRNA levels in the hypothalamus, 
and brain sections from offspring of RIP-Cre mice mated with Rosa26YFP-stopfl/fl reporter mice showed only 
very few and sporadic YFP + cells. Additionally, in our experiments both control and mutant mice were all het-
erozygous for RIP-Cre, with maternal inheritance of the transgene. This design thus rules out a contribution of 
the Cre transgene on the observed mutant phenotypes. In most experiments reported by Modi et al., only the 
mutants inherited an Ins1-Cre allele. Although hemizygosity for Ins1 gene has no phenotypic impact on glucose 
 homeostasis44, Cre recombinase expression has the potential to lead to changes in the pancreatic β-cells’ physi-
ology (albeit the Ins1-Cre line has been carefully verified for lack of activity in the central nervous system and 
transmission of Ins1-Cre has been reported to not affect glucose homeostasis up until the age of 12  weeks45). 
Third, differences in HFD composition, age at feeding and length of exposure may be responsible for some of 
the diverging phenotypic outcomes. Indeed, Modi et al. performed the ipGTT challenge after a longer exposure 
to HFD diet (18 weeks compared to 12–14 weeks in the experiments reported in our study) and they used a diet 
with 45% energy derived from fat (60% in our study). The ages of various cohorts of mice used in the two studies 
were also distinct. Overall, these experimental differences call for caution when trying to draw direct comparisons 
between the two Igf2βKO models. One of the common observations between our studies is that Igf2βKO females 
seem more susceptible to develop altered glucose homeostasis than Igf2βKO males when exposed to increased 
metabolic demand. Sex-related differences in β-cell function under stress conditions have been observed before 
in many clinical studies and in animal models of  diabetes46. Estrogen acting on β-cells via ERα (estrogen receptor 
type α) promotes cell survival and insulin biosynthesis, and enhances GSIS through ERβ47. Interestingly, Igf2 is a 
known estrogen-responsive gene, at least in some tissues such as the  hippocampus48, and sex-related expression 
differences during development in organs such as the  brain49 have been documented. Mody et al. proposed an 
interplay between estrogens and the IGF2 autocrine actions in controlling β-cell mass and function in female 
mice. Our results further suggest that Igf2 may be one of the genes that mediate the protective actions of estrogen 
on pancreatic β-cells in females, under conditions of increased metabolic demand.
Given that IGF2 expression timing in mouse and human are different, is there any relevance for our findings 
regarding IGF2 actions in human β-cells? A significant number of genome-wide association studies (GWAS) have 
linked T2D with the human INS-IGF2  locus6,50, as well as with the IGF2BP2  locus51 that plays an important role 
in IGF2 mRNA  translation52. A loss-of-function splice acceptor IGF2 variant was found to protect against  T2D53. 
None of the above studies can point directly to a defect in β-cell function. However, some studies provide a more 
direct link. Human pancreatic islets express a hybrid protein INS-IGF2 that consists of the pre-proinsulin signal 
peptide, the insulin B-chain, and eight amino acids of the C-peptide in addition to 138 amino acids encoded 
by the IGF2 gene. INS-IGF2 expression was lower in pancreatic islets of T2D donors compared to  controls54. 
Figure 4.  Impact of Igf2βKO on body weight, body composition and glucose homeostasis in mice fed a 
HFD. (a) Growth kinetics in female and male cohorts (n = 12–15 mice/group) (b) Absolute fat mass content 
measured by TD-NMR in 40 week old female and male mice (n = 12–15 mice/group). (c) Absolute lean mass 
content measured by TD-NMR in 40 week old female and male mice (n = 12–15 mice/group). (d) and (e) Left: 
insulin tolerance tests (ITTs) performed in 40 week old females (d) or males (e) after 6 h fasting. The graphs 
show changes in blood glucose concentrations (y-axis), from basal pre-treatment values, with time (x-axis), 
after insulin administration. Right: area under curve (AUC), calculated during ITT using the trapezoid rule, 
normalised to basal glucose levels (n = 9–12 mice/group). (f) and (g) Left: OGTTs performed in 41 week old 
females (f) or males (g) after 6 h fasting. The graph shows changes in blood glucose concentrations (y-axis), 
from basal pre-treatment values, with time (x-axis), after glucose administration. Right: AUC, calculated 
during OGTT using the trapezoid rule, normalised to basal glucose levels (n = 12–15 mice/group). (h) Left: 
GSIS in 41 week old females. Right: AUC, calculated using the trapezoid rule, normalised to basal insulin levels 
(n = 9–13 females/group). (i) Measurement of pancreatic β-cell mass by stereology in 42 week old mice (n = 6–7 
mice/group). Data is presented as averages ± SD (a), averages ± SEM [left-side graphs in panels (d)–(h)], or 
individual values with averages ± SD [panels (b), (c), right-side graphs in panels (d)–(h) and panel (i)]. P values 
shown above graphs were calculated by mixed-effects model tests [panels (a)], or two-way ANOVA [panels (b), 
(c), right-side graphs in panels (d)–(h) and panel (i)], * corresponds to p < 0.05 calculated by Sidak’s multiple 
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Notably, INS (38%), INS-IGF2 (10%) and IGF2 (2%) were the top three most abundant transcripts expressed in 
human β-cells isolated from donors without  diabetes55. Finally, some forms of insulinomas, endocrine pancreatic 
tumours that lead to severe forms of hyperinsulinemic hypoglycaemia, associated hypermethylation at the IGF2 
differentially methylated region 2 (IGF2-DMR2), with IGF2 loss-of-imprinting and  overexpression56.
Our study has a number of limitations. First, we cannot fully exclude that the RIP-Cre line used in our study 
has an impact on β-cell physiology that could influence the differences observed when comparing controls to 
Igf2βKO mutants. Other β-cell Cre drivers have been previously shown to induce impaired islet function due to 
the expression of a human growth hormone (hGH) minigene, which was frequently used to enhance transgene 
 activity57. The RIP-Cre line used in this study does not contain the hGH  minigene58. However, a more subtle 
impact on β-cell function may still exist. Second, we cannot separate, in our study, autocrine IGF2 actions in 
early life, when Igf2 mRNA levels are much higher, from those in adult life, when Igf2 mRNA levels are very low, 
but still detectable. A direct proof that the observed phenotypes are due to programming effects of autocrine 
IGF2 in early life, as suggested, would require the use of inducible β-cell-specific Cre lines that enable temporal 
control of Cre  recombination59. Third, we cannot exclude a contribution of miR-483, a microRNA embedded 
within intron 4 of Igf2 and deleted in our model, to the phenotypes observed in Igf2βKO mutants. Previous 
in vitro data obtained in MIN6 insulin-secreting cells, has shown that miR-483 promotes insulin transcription 
Figure 5.  Impact of Igf2βKO on body weight and glucose homeostasis in Lepob/ob in 8 week old male and female 
mice (a) Body weights. (b) Glucose levels in peripheral blood measured after overnight fasting. (c) ipGTTs 
performed after overnight fasting. First and third graphs show changes in blood glucose concentrations (y-axis), 
from basal pre-treatment values, with time (x-axis), after glucose administration. Second and fourth graphs 
show AUCs, calculated during ipGTT using the trapezoid rule, normalised to basal glucose levels. (d) ITTs 
performed after overnight fasting. First and third graphs show changes in blood glucose concentrations (y-axis), 
from basal pre-treatment values, with time (x-axis), after insulin administration. Second and fourth graphs show 
AUCs, calculated during ITT using the trapezoid rule, normalised to basal glucose levels. For all graphs, data is 
presented as individual values, with averages ± SD [panels (a) and (b) and second plus fourth graphs in panels 
(c) and (d)] or as averages ± SEM [first and third graphs in panels (c) and (d)]; n = 6–10 mice/group. Different 
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and secretion by targeting SOCS3, a member of suppressor of cytokine signalling  family60. Fourth, we did not 
explore the impact of Igf2βKO in the context of ageing, which is one of the well-known risk factors for type 2 
diabetes  development61. Aged mice are considered to be those older than 18 months, which has been suggested 
to be equivalent to 56 + in human  years62. In the cohorts of mice fed normal chow or HFD, we did not extend the 
follow-up beyond 10 months. We cannot exclude that Igf2βKO would develop diabetes when significantly older. 
Fifth, for the cohort of mice fed HFD, the phenotypic studies were conducted after 12–14 weeks of exposure, 
similar to timelines reported in other studies using conditional deletions in pancreatic β-cells63–65. However, we 
cannot exclude that more prolonged HFD feeding is required for Igf2βKO mice to reach their maximum capacity 
for β-cell mass expansion, leading to more severe glucose intolerance compared to controls. Sixth, combinations 
of stress conditions, such as pregnancy associated with HFD feeding, or ageing and HFD feeding may be required 
to uncover β-cell functional defects induced by the Igf2βKO mutation. Lastly, the autocrine IGF2 actions may be 
masked by the paracrine actions of IGF2 produced by neighbouring cells. In our previous study we observed 
that mice lacking mesenchyme-derived IGF2 have reduced β-cell mass and develop glucose intolerance during 
 pregnancy18. We also observed significant expression of Igf2 mRNA in the endothelial cells. Other endocrine 
cells within the islets of Langerhans may also affect β-cell plasticity via paracrine IGF2 actions. Combinations of 
conditional deletions in multiple cell types, aimed at reducing the paracrine IGF2 actions may uncover additional 
roles of autocrine IGF2 in pancreatic β-cells.
In summary, we report in this study that autocrine actions of IGF2, although not required for development 
of pancreatic β-cells, have a long-term impact on β-cell plasticity that becomes apparent in female mice under 
conditions associated with increased demand for insulin. Our results also highlight that even subtle defects in 
maternal pancreatic β-cell function can affect the normal development and physiology of the descendants, with 
potential implication for metabolic health in later life.
Methods
Ethics statement. This study was carried out in compliance with the ARRIVE  guidelines66. The research 
has been regulated under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following 
ethical review and approval by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB) 
and by the Ethical and Veterinary committees of Rey Juan Carlos University in Spain. All mouse experiments 
were approved and performed under PPL No. 80/2483 (study 2483/02/12), PPL No. 80/2484 (study 2484/38/12) 
and PPL No. 70/7594 (study 7594/4/15).
Mouse strains and husbandry. Igf2fl/+ mice were generated in our laboratory, as  described18. C57BL/6J 
mice were purchased from Charles River (Kent, UK). Rosa26YFP-stopfl/fl reporter  mice24 were kindly provided 
by Dr. Martin Turner (The Babraham Institute, Cambridge). RIP-Cre mice that carry a Cre transgene under 
the control of the rat Ins2 (insulin 2) promoter (RIP), which directs expression to insulin-positive β-cells from 
approximately E8.5–9  onwards23, were obtained from Central Biomedical Services (CBS Transgenic Services, 
University of Cambridge). Lepob/+ mice that have a spontaneous mutation in the Lep gene encoding  leptin67 were 
available at the Universidad Rey Juan Carlos mouse facility. All lines were maintained onto an inbred C57BL/6J 
genetic background for > 10 generations prior to the experiments performed in this study.
Mice were fed a standard chow diet with 9% of kcal from fat (SDS, Essex, UK), or a high fat diet (HFD) con-
taining 60% kcal from fat (D12492, Research diets Inc., New Brunswick, USA) and housed with a 12-h light/dark 
cycle in a temperature-controlled room (22 °C). Food and water were available ad libitum, except for periods 
of fasting when food was withdrawn. For timed matings, the day of detection of a vaginal plug was noted as 
embryonic day 1 (E1) and the day of birth was noted as post-natal day 0 (P0). Mice were weaned at 3 weeks of 
age and ear notches were used for visual identification and genotyping, which was performed using standard 
PCR or qPCR (quantitative PCR—in order to discriminate between RIPCre/+ and RIPCre/Cre) with primers listed 
in Supplementary Table 1. Genotyping for the mouse obese (ob) mutation at the Lep locus was performed by 
PCR and restriction fragment length polymorphism (RFLP) analysis, as  described68.
Fluorescence‑activated cell sorting (FACS). P2 pups were sacrificed by decapitation. Then, pancre-
ases were dissected under a dissection microscope and dissociated into single cells with trypsin–EDTA (Sigma 
Aldrich), at 37 °C, for 20 min. After washing with ice-cold PBS, cells were passed through 70 μm strainers and 
single-cell suspensions were sorted into  YFP+ and  YFP- fractions using an Aria-Fusion cell sorter (BD Biosci-
ence). Dead cells were excluded based on forward and side scatter profiles and the uptake of 7AAD (7-Ami-
noactinomycin D dead cell stain, Life Technologies). Sorted  YFP+ cells were pelleted by centrifugation and flash 
frozen using liquid nitrogen (N2), and then stored at -80 °C until use.
qRT‑PCR analysis. Total RNA was extracted from FACS-isolated β-cells and other organs using RNeasy Plus 
Kits (Qiagen—74134 and 74034). RNA concentration was measured by NanoDrop (Thermo Scientific) and qual-
ity was assessed in agarose gels. RNA extracted from FACS-isolated β-cells was quantified and assessed for quality 
using the RNA 6000 Pico Kit (Agilent—5067-1513) and an Agilent 2100 Bioanalyzer. Reverse transcription was 
performed using the RevertAid RT Reverse Transcription Kit (ThermoFisher—K1622). In the case of total RNA 
extracted from FACS-isolated β-cells, cDNA was produced using the QuantiTect Whole Transcriptome Kit (Qiagen) 
following manufacturer’s instructions. qRT-PCR was performed with the SYBR Green JumpStart Taq Ready Mix 
(Sigma—S4438) and custom-made primers (Supplementary Table 2) using an ABI Prism 7900 system (Applied 
Biosystems). Gene expression normalisation was performed against three housekeeping genes: Ppia (peptidylpropyl 
isomerase A or cyclophilin-A), Gapdh (glyceraldehyde 3-phosphate dehydrogenase) and Sdha (succinate dehydro-
genase complex flavoprotein subunit A). Relative levels of expression were calculated using the  2−ΔΔCt  method69.
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Immunostainings, cell counting and β‑cell mass analyses. Pancreases and brains were dissected 
(using a stereoscope for the early post-natal analyses), fixed in 4% paraformaldehyde in PBS overnight, dehy-
drated and then embedded in paraffin. Paraffin blocks were cut at 5 μm thickness, sections were then deparaffin-
ised, rehydrated, stained and mounted with coverslips. Insulin and YFP stains and β-cell mass measurements 
using pancreas stereology were performed as previously  described18. Measurements of β-cell proliferation were 
preceded by intraperitoneal injections with 50 µg of 5-ethynyl-2′-deoxyuridine (EdU)/g body weight, 6 h prior 
to tissue collection. EdU staining was done using the Click-iT EdU Alexa Fluor 488 Imaging Kit (Invitrogen—
C10337), according to manufacturer’s instructions. TUNEL staining was performed using the In Situ Cell Death 
Detection Kit, TMR red (Sigma—012156792910), according to manufacturer’s protocol. For immunofluores-
cence stains, Hoechst33342 (Sigma—B2261) or DAPI (Sigma—D9542) were used to label the nuclei. Immu-
nofluorescence image acquisition was performed as Z-stacks using a LSM510 Meta confocal laser scanning 
microscope (Carl Zeiss, Jena, Germany) and the ZEN 2009 software. Counting proliferating β-cells  (EdU+/INS+) 
and apoptotic β-cells  (TUNEL+/INS+) was performed using Volocity 6.3 (Improvision).
Body composition. Body composition analysis was performed by time-domain nuclear magnetic reso-
nance spectroscopy (TD-NMR) that measures total body fat mass and lean  mass70. For this purpose, live and 
conscious mice were placed inside the Minispec Live Mice Analyser (Bruker Minispec Live Mice Analyser LF50).
Glucose and insulin tolerance tests. Oral glucose tolerance tests (OGTTs), intra-peritoneal glucose tol-
erance tests (ipGTTs) and insulin tolerance tests (ITTs) were performed on conscious mice after 6 h fasting (8am 
to 2 pm—for OGTTs performed on pregnant females, for OGTTs and ITTs on mice fed HFD, and for ITTs for 
the cross with Lepob/+ mice) or 16 h fasting (5 pm to 9am following day—for ipGTTs performed on adult mice 
fed chow diet and for the cross with Lepob/+ mice). Throughout these experiments, mice were kept in heated 
cages (32 °C) to facilitate blood collection from the tail vein. Blood samples, taken from the tail vein immediately 
before the start of each experiment, were used to measure glucose and/or insulin levels in the fasting state. For 
OGTT, glucose was administered by oral gavage at a dose of 2 mg/g body weight (adjusted per individual animal 
for the pregnancy experiment or fixed volume calculated for an averaged body weight for the HFD experiment). 
For ipGTTs, glucose was administered by i.p. injection at a dose of 1 mg/g body weight. For ITTs performed 
on mice fed HFD, insulin was administered by i.p. injection at a dose of 0.75mUI/g body weight for females 
and 1mUI/g body weight for males (fixed volume calculated for an averaged body weight). For ITTs performed 
for the cross with Lepob/+ mice, same dose of 0.75mUI/g body weight was used for both sexes. Throughout the 
experiments, glucose measurements were performed using a glucose meter and test strips (AlphaTRAK). The 
areas under the curve (AUCs) following OGTTs, ipGTTs or ITTs were calculated by the trapezoidal rule.
Plasma insulin and total pancreas insulin measurements. Blood samples for plasma insulin meas-
urements were collected in heparinised capillary tubes during OGTT experiments at 0, 15, 30, 45 and 60 min. 
Tubes were kept on ice and spun at 4,000 RPM (rotations per minute) for 5 min. Plasma samples were flash 
frozen in liquid N2 and stored at -80 °C until analysis. For total pancreas insulin measurements, whole pancre-
ases were flash frozen in liquid N2, then pulverised and re-suspended in cold acid–ethanol and stored at 4 °C 
for 48 h, with sonication every 24 h during the storage. Insulin levels in plasma and acid–ethanol supernatants 
were measured using ELISA kits (Meso Scale Discovery Mouse/Rat Insulin Assay Kit) at CBAL (Core Biochemi-
cal Assay Laboratory, Addenbrooke’s hospital). Total pancreas insulin content (ng) was normalised to the total 
pancreas wet weight (mg), measured at collection.
Blood biochemistry. Serum glucose, triglycerides, free (non-esterified) fatty acids, and total cholesterol 
concentrations were measured using enzymatic assay kits. Briefly, glucose was measured based on an adapta-
tion of the hexokinase-glucose-6-phosphate dehydrogenase method using a kit from Siemens Healthcare (prod-
uct code DF30). Triglycerides were measured using an enzymatic assay kit from Siemens Healthcare (product 
code DF69A) that combines activities of lipoprotein lipase, glycerol kinase and glycerol-3-phosphate oxidase. 
Total cholesterol was measured using an enzymatic assay kit from Siemens Healthcare (product code DF27) 
that combines activities of cholesterol esterase and cholesterol oxidase. The assays for glucose, triglycerides and 
total cholesterol were automated on the Siemens Dimension EXL analyser. Free (non-esterified) fatty acids were 
measured using Roche’s Free Fatty Acid Kit (half-micro test) (Sigma Aldrich product code 11383175001) that 
is based on the enzymatic conversion of free fatty acids to acyl CoA by acyl-Co A synthetase. Leptin, adiponec-
tin and resistin measurements were performed using enzyme-linked immunosorbent assay kits manufactured 
by MesoScale Discovery (MSD) Rockville, MD, USA, on a MSD s600 instrument, according to manufacturer 
instructions (K152BYC kit for leptin, K152BXC kit for adiponectin and K152FNC kit for resistin). All blood 
biochemistry measurements were performed at CBAL, Addenbrooke’s hospital.
Statistical analyses. Statistical analyses were performed using GraphPad Prism 8 software. For two groups, 
statistical analyses were performed using Mann–Whitney tests or un-paired Student’s t-tests with Welch’s correc-
tion (depending on the outcome of Shapiro–Wilk tests for normal distribution). Where more than two groups 
were analysed, we used one-way ANOVA, followed by Tukey’s multiple comparisons tests or two-way ANOVA 
followed by Sidak’s corrections for multiple testing, as appropriate. For growth kinetics analyses, we used mixed-
effects model (REML) tests. For all tests, P values < 0.05 were considered significant. Detailed results of statistical 
analyses are shown in Supplementary Table 3.
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